Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

Lim, Seung Woon; Park, Jooho; Shim, Man Kyu; Um, Wooram; Yoon, Hong Yeol; Ryu, Jee Hoon; Lim, Dong Kwon; Kim, Kwangmeyung

doi:10.7150/thno.38425

Cited by 119 publications

(64 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cumulative concentration of drugs can be increased in targeted tissues by means of the application of liposomes since they alter the biological distribution of the drugs. This phenomenon can be very useful because the other normal organs would not be affected by the deleterious impacts of anticancer drugs that can lead to the lower harmful effects . In the present study, we entrapped cisplatin in PEGylated nanoliposomes, and then, the characteristics and cytotoxicity of them were studied.…”

Section: Introductionmentioning

confidence: 96%

Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy

Ghafari

Haghiralsadat

Falahati-Pour

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cisplatin is one of the conventional drugs used in chemotherapy which has a potent antitumor function. However, due to the dangerous side effects, including the damage to DNA of the normal cells, its clinical use is limited. The aim of this study was to prepare and characterize nanoliposome containing cisplatin. We optimized liposome formulations through the modification of the proportion of SPC80 (soybeanphospholipids with 75% phosphatidylcholine) and cholesterol content. Then, novel PEGylated liposomal formulations containing SPC80: cholesterol: DSPE-mPEG (at ratios of 85:10:5) were designed and developed to serve as a therapy to achieve more improved pharmaceutical efficiency. Zeta Sizer showed that PEGylated nanoliposomes had a mean diameter of 119.7 ± 2.1 nm, a zeta potential of −26.03 ± 1.34 mV, and entrapment efficiency of 96.65 ± 3%. The optimum formulations represented sustained, thermo-sensitive release, and augmented cellular uptake. The cytotoxic effect of the liposomal drug was higher than the free medication drug that confirmed the efficiency of cellular uptake. This study suggests that nanoliposome-loaded cisplatin plays a vital role in improving drug efficacy and the reduction of dosage. K E Y W O R D Sbreast cancer, chemotherapy, cisplatin, nanoliposome

show abstract

Section: Introductionmentioning

confidence: 96%

Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy

Ghafari

Haghiralsadat

Falahati-Pour

et al. 2020

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…The 2018 Nobel Prize in physiology or medicine was awarded to pioneers in the field of cancer immunotherapy, which has been a tremendously successful area of work [45]. Tumor immunotherapy has been widely explored in various fields, such as nanotechnology-enhanced immunotherapy [46,47].…”

mentioning

confidence: 99%

Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study

Deng

Jin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. The prognosis of pancreatic adenocarcinoma (PAAD) is extremely poor and has not been improved. Thus, an effective method to assess the prognosis of patients must be established to improve their survival rate. Method. This study investigated immune-related genes that could be used as potential therapeutic targets for PAAD. Level 3 gene expression data from the PAAD cohort and the relevant clinical information were obtained from The Cancer Genome Atlas (TCGA) database. For validation, other PAAD datasets (DSE62452) were downloaded from the Gene Expression Omnibus (GEO) database. The PAAD datasets from TCGA and GEO were used to screen immune-related genes through the Molecular Signatures Database using gene set enrichment analysis. Then, the overlapping immune-related genes of the two datasets were identified. Coexpression networks of the immune-related genes were constructed. Results. A signature of three immune-related genes (CKLF, ERAP2, and EREG) was identified in patients with PAAD. The signature could be used to divide the patients with PAAD into high- and low-risk groups based on their median risk score. Multivariate Cox regression analysis was performed to determine the independent prognostic factors of PAAD. Time-dependent receiver operating characteristic (ROC) curve analysis was conducted to assess the prediction accuracy of the prognostic signature. Last, a nomogram was established to assess the individualized prognosis prediction model based on the clinical characteristics and risk score of the TCGA PAAD dataset. The accuracy of the prognostic signature was further evaluated through functional evaluation and principal component analysis. Conclusions. The results indicated that the signature of three immune-related genes had excellent predictive value for PAAD. These findings might help improve personalized treatment and medical decisions.

show abstract

“…Investigation into the mechanisms behind the trigger for this anti-tumor immunity remains an interesting pursuit. Notably, recent studies have found that certain chemotherapies 38 , PTT 39 , photodynamic therapy 40 - 42 and other treatments 43 - 45 can initiate an antitumor immune response by inducing tumor cells to undergo immunogenic cell death (ICD). Furthermore, cancer cells undergoing ICD can release immunostimulatory damage-associated molecular patterns (DAMPs) that act as potent danger signals, including calreticulin (CRT) exposure on the surface of tumor cells, release of large amounts of high-mobility group box 1 (HMGB1) or extracellular secretion of adenosine triphosphate (ATP).…”

Section: Resultsmentioning

confidence: 99%

ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death

Zhang

Guo²,

Liu³

et al. 2020

Theranostics

View full text Add to dashboard Cite

Rationale: The development of a highly effective and tumor-specific therapeutic strategy, which can act against the primary tumor and also condition the host immune system to eliminate distant tumors, remains a clinical challenge. Methods: Herein, we demonstrate a facile yet versatile ZnO-capping and Doxorubicin (DOX)-loaded multifunctional nanocomposite (AuNP@mSiO 2 @DOX-ZnO) that integrates photothermal properties of gold nanoparticles (NPs), pH-responsive properties and preferential selectivity to tumor cells of ZnO QDs and chemotherapeutic agent into a single NP. The photothermal performance, pH-triggered release and preferential phagocytic ability were assessed. The induced anti-tumor immunity was determined by analyzing immune cell profile in tumor in vivo and molecular mechanism were identified by detecting expression of immunogenic cell death (ICD) markers in vitro . Moreover, mice models of unilateral and bilateral subcutaneous melanoma and lung metastasis were established to evaluate the antitumor effects. Results: As an efficient drug carrier, ZnO-capped NPs guarantee a high DOX payload and an in vitro , efficient release of at pH 5.0. In murine melanoma models, the nanocomposite can significantly inhibit tumor growth for a short period upon low-power laser irradiation. Importantly, ZnO NPs not only demonstrate preferential selectivity for melanoma cells but can also induce ICD. Meanwhile, AuNP@mSiO 2 -based photothermal therapy (PTT) and DOX are directly cytotoxic towards cancer cells and demonstrate an elevated ICD effect. The induced ICD promotes maturation of dendritic cells, further stimulating the infiltration of effector T cells into tumor sites, preventing tumor growth and distant lung metastases. Conclusions: This study highlights the novel mechanism of ZnO-triggered anti-tumor immunity via inducing ICD. Additionally, we shed light on the multifunctionality of nanocomposites in delivering localized skin tumor therapy as well as inhibiting metastatic growth, which holds great promise in clinical applications.

show abstract

Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy

Cited by 119 publications

References 134 publications

Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy

Development of a novel liposomal nanoparticle formulation of cisplatin to breast cancer therapy

Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study

ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death

Contact Info

Product

Resources

About